Spots Global Cancer Trial Database for A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
Official Title: A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Study ID: NCT03099109
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Arizona Cancer Center, Tucson, Arizona, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Columbia University College of Phys & Surgeons, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The START Center for Cancer Care, San Antonio, Texas, United States
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
Seoul National University Hospital, Seoul, , Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, , Korea, Republic of
Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain
Fundación Jiménez Díaz-Oncology, Madrid, , Spain
Hospital Madrid Norte Sanchinarro, Madrid, , Spain
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
